[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a95d88f38b1ed271986f5de3de2a4ce9dff0fa6b475ca908a0e5cf53bf3b4912",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734540300,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "id": 132150454,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a95d88f38b1ed271986f5de3de2a4ce9dff0fa6b475ca908a0e5cf53bf3b4912"
    }
  },
  {
    "ts": null,
    "headline": "REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study",
    "summary": "Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.",
    "url": "https://finnhub.io/api/news?id=ae9dcd56406f072d7b3ede66d68e08c53dafcaa78c984390c930ad5cb6dcad16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734535020,
      "headline": "REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study",
      "id": 132048038,
      "image": "https://media.zenfs.com/en/zacks.com/83114bcf5a91754ed7ae3f6080390cd9",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.",
      "url": "https://finnhub.io/api/news?id=ae9dcd56406f072d7b3ede66d68e08c53dafcaa78c984390c930ad5cb6dcad16"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains",
    "summary": "GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.",
    "url": "https://finnhub.io/api/news?id=fc10686f69a3b951a15d97d3358a397ef18bcad2457c936da3f1e9be390c8bff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734531780,
      "headline": "Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains",
      "id": 132040766,
      "image": "https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.",
      "url": "https://finnhub.io/api/news?id=fc10686f69a3b951a15d97d3358a397ef18bcad2457c936da3f1e9be390c8bff"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals - EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals In Patients with Macular Edema following Retinal Vein Occlusion",
    "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD Injection 8 mg for the treatment of patients with macular...",
    "url": "https://finnhub.io/api/news?id=4b3b6d2c1c48b28b16de55ef471826062bb1890f14244a2669474e3c3c146342",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734518028,
      "headline": "Regeneron Pharmaceuticals - EYLEA HD Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals In Patients with Macular Edema following Retinal Vein Occlusion",
      "id": 132039390,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the primary endpoint was met in the Phase 3 QUASAR trial investigating EYLEA HD Injection 8 mg for the treatment of patients with macular...",
      "url": "https://finnhub.io/api/news?id=4b3b6d2c1c48b28b16de55ef471826062bb1890f14244a2669474e3c3c146342"
    }
  }
]